This regulatory relationship highlights CHAC1’s potential role in modulating oncogenic signaling pathways, making it a candidate for targeted therapy in diseases like uveal melanoma where PI3K/AKT signaling is dysregulated (Liu et al., 2019). This evidence concerns the gene CHAC1 and uveal melanoma.